Sign in
4

Changes in Ownership

Contineum Therapeutics, Inc. Filed Acc 0001628280-26-047909

Chief Scientific Officer sold 1,040 shares at $16.00 ($16,640)

  • Chief Scientific Officer acquired 1,040 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Lorrain Daniel S. Chief Scientific Officer 2026-07-08 Option exercise 10b5-1 +1,015 $1.01 $1,025 136,217 D: show line 1 in the form
Lorrain Daniel S. Chief Scientific Officer 2026-07-08 Sale 10b5-1 −1,015 $16.00 $16,240 135,202 D: show line 2 in the form
Lorrain Daniel S. Chief Scientific Officer 2026-07-09 Option exercise 10b5-1 +25 $1.01 $25 135,227 D: show line 3 in the form
Lorrain Daniel S. Chief Scientific Officer 2026-07-09 Sale 10b5-1 −25 $16.00 $400 135,202 D: show line 4 in the form
Open-market sales · 1,040 sh · avg $16.00 · $16,640

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Lorrain Daniel S. Chief Scientific Officer 2026-07-08 Option exercise · Stock Option (right to buy) 10b5-1 −1,015 33,282 D: show line 5 in the form
Lorrain Daniel S. Chief Scientific Officer 2026-07-09 Option exercise · Stock Option (right to buy) 10b5-1 −25 33,257 D: show line 6 in the form
Loading xslF345X06/wk-form4_1783718438.xml…